ACRS 8-K 2026-10-27
Aclaris Therapeutics, Inc. (ACRS) 8-K dated 2026-10-27 — accession 0001104659-26-118952. This URL is the filing, not the ACRS hub.
Aclaris Therapeutics, Inc. (ACRS) is a biotechnology company listed on NASDAQ.
ACRS: SECURITIES AND EXCHANGE COMMISSION
Cached items: 2.02, 7.01, 8.01, 9.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.
Latest reported ACRS revenue for 2025-12-31 was $7.8M. Net income was -$64.9M. Revenue was down 58.2% from 2024-12-31 to 2025-12-31. ACRS currently screens at market cap $615.9M.
Not investment advice. The ACRS SEC hub lists recent forms. The stock page is the research view.
- Guidance
- expects to provide an update regarding plans for the potential development of ATI-052 in an additional indication in the near t
Why it matters
- expects to provide an update regarding plans for the potential development of ATI-052 in an additional indication in the near t